Scott Haden Kollins

Scott Haden Kollins

Professor in Psychiatry and Behavioral Sciences

External Address: 
2608 Erwin Road Lakeview Pavi, Durham, NC 27705
Internal Office Address: 
Box 3527 Med Ctr, Durham, NC 27710
Phone: 
919.681.0014

Overview

Scott H. Kollins, PhD received his undergraduate degree in psychology from Duke and his Master’s and Doctorate degrees in Clinical Psychology from Auburn University. After completing his clinical internship at the University of Mississippi Medical Center, where he served as Chief Intern, he joined the faculty of the Department of Psychology at Western Michigan University for three years, before joining the Duke faculty in 2000. Dr. Kollins has published more than 125 scientific papers in peer-reviewed journals.  Over the past 10 years, his research has been supported by 6 different federal agencies, including NICHD, NIDA, NIMH, NIEHS, NINDS, and EPA, and he currently holds a mid-career K24 award from NIDA.  He has also served as PI on more than 40 industry-funded clinical trials and is a consultant to a number of pharmaceutical companies in the area of ADHD clinical psychopharmacology.  He has served as a standing member of the Child Psychopathology and Developmental Disabilities study section and also served as an ad-hoc reviewer for 10 additional NIH study sections and 7 international granting agencies. He is an Associate Editor for the Journal of Attention Disorders and has reviewed for more than 50 different peer-reviewed journals. He is an elected member of the College on Problems of Drug Dependence and the American College of Neuropsychopharmacology. Dr. Kollins is a licensed clinical psychologist and maintains a practice through the ADHD Program’s outpatient clinic. His research interests are in the areas of psychopharmacology and the intersection of ADHD and substance abuse, particularly cigarette smoking.

Education & Training

  • Ph.D., Auburn University 1997

Selected Grants

Duke Women's Reproductive Health Research Scholars awarded by National Institutes of Health (Mentor). 2020 to 2025

Novel Approaches to Infant Screening for ASD in Pediatric Primary Care awarded by National Institutes of Health (Co Investigator). 2019 to 2024

Unified Program for Therapeutics in Children awarded by National Institutes of Health (Preceptor). 2019 to 2024

Scalable Computational Platform For Active Closed-Loop Behavioral Coding in Autism Spectrum Disorder awarded by National Institutes of Health (Consultant). 2019 to 2023

Duke CTSA (TL1) awarded by National Institutes of Health (Mentor). 2018 to 2023

Dyanavel Safety Study awarded by Tris Pharma, Inc. (Principal Investigator). 2019 to 2022

Co-occurring ADHD in young children with ASD: Precursors, detection, neural signatures, and early treatment awarded by National Institutes of Health (Co-Principal Investigator). 2017 to 2022

Mobile health interventions for varenicline adherence among HIV-positive smokers awarded by National Institutes of Health (Co-Mentor). 2017 to 2022

Dyanavel Efficacy Study awarded by Tris Pharma, Inc. (Principal Investigator). 2019 to 2021

Sleep Dysfunction and Neurocognitive Outcomes in Adolescent ADHD awarded by National Institutes of Health (Mentor). 2016 to 2021

Pages

Kollins, S. H., and F. J. McClernon. “ADHD and smoking.” Attention-Deficit Hyperactivity Disorder in Adults and Children, 2015, pp. 327–42. Scopus, doi:10.1017/CBO9781139035491.027. Full Text

Mitchell, J. T., and S. H. Kollins. “ADHD in adolescence.” Adolescent Health Psychology, edited by W. O’Donohue et al., Springer, 2013, pp. 423–45.

Mitchell, J. T., and S. H. Kollins. “Attention-deficit/hyperactivity disorder in adolescence.” Handbook of Adolescent Health Psychology, 2013, pp. 423–45. Scopus, doi:10.1007/978-1-4614-6633-8_27. Full Text

Kollins, S. H. “Abuse potential of stimulant drugs used to treat ADHD.” ADHD in Adults: Characterization, Diagnosis, and Treatment, 2011, pp. 230–39. Scopus, doi:10.1017/CBO9780511780752.020. Full Text

Lunsford-Avery, Jessica R., et al. “Sluggish Cognitive Tempo in Adults Referred for an ADHD Evaluation: A Psychometric Analysis of Self- and Collateral Report.J Atten Disord, vol. 25, no. 3, Feb. 2021, pp. 322–31. Pubmed, doi:10.1177/1087054718787894. Full Text

Addicott, Merideth A., et al. “Attention-deficit/hyperactivity disorder and the explore/exploit trade-off.Neuropsychopharmacology, vol. 46, no. 3, Feb. 2021, pp. 614–21. Pubmed, doi:10.1038/s41386-020-00881-8. Full Text

Maguire, Rachel L., et al. “Associations between maternal obesity, gestational cytokine levels and child obesity in the NEST cohort.Pediatr Obes, Dec. 2020, p. e12763. Pubmed, doi:10.1111/ijpo.12763. Full Text

Dew, Rachel E., et al. “ADHD, Religiosity, and Psychiatric Comorbidity in Adolescence and Adulthood.J Atten Disord, Dec. 2020, p. 1087054720972803. Pubmed, doi:10.1177/1087054720972803. Full Text

Mitchell, John T., et al. “Sluggish cognitive tempo (SCT) in an adult outpatient sample seeking an attention-deficit/hyperactivity disorder assessment: Age of onset and assessment method impact on SCT rates.J Psychiatr Res, vol. 131, Dec. 2020, pp. 203–08. Pubmed, doi:10.1016/j.jpsychires.2020.09.013. Full Text

Ksinan, Albert J., et al. “Identifying the best questions for rapid screening of secondhand smoke exposure among children.Nicotine Tob Res, Nov. 2020. Pubmed, doi:10.1093/ntr/ntaa254. Full Text

Engelhard, Matthew M., et al. “Health system utilization before age 1 among children later diagnosed with autism or ADHD.Sci Rep, vol. 10, no. 1, Oct. 2020, p. 17677. Pubmed, doi:10.1038/s41598-020-74458-2. Full Text

Lunsford-Avery, Jessica R., et al. “Eveningness Diurnal Preference: Putting the "Sluggish" in Sluggish Cognitive Tempo.J Atten Disord, Oct. 2020, p. 1087054720959697. Pubmed, doi:10.1177/1087054720959697. Full Text

Adjei, Akwete L., et al. “A Pharmacokinetic Study of Methylphenidate Hydrochloride Multilayer Extended-Release Capsules (Aptensio XR®) in Preschool-Aged Children with Attention-Deficit/Hyperactivity Disorder.Paediatr Drugs, vol. 22, no. 5, Oct. 2020, pp. 561–70. Pubmed, doi:10.1007/s40272-020-00409-z. Full Text

Pages

Kollins, Scott H., et al. “5.25 STARS-ADJUNCT: A HOME-BASED, DIGITAL TREATMENT FOR PEDIATRIC ADHD AS ADJUNCT TO STIMULANT MEDICATION: INSIGHTS ON REPEAT ADMINISTRATION AND THE STABILITY OF EFFECTS.” Journal of the American Academy of Child & Adolescent Psychiatry, vol. 59, no. 10, Elsevier BV, 2020, pp. S157–S157. Crossref, doi:10.1016/j.jaac.2020.08.086. Full Text

Davis, Naomi, et al. “5.27 STARS-ADJUNCT: AKL-T01, A HOME-BASED DIGITAL INTERVENTION AS AN ADJUNCT TO STIMULANT MEDICATION FOR PEDIATRIC ADHD: ACADEMIC PERFORMANCE AND RELATION TO OBJECTIVE MEASURES OF ATTENTION.” Journal of the American Academy of Child & Adolescent Psychiatry, vol. 59, no. 10, Elsevier BV, 2020, pp. S157–58. Crossref, doi:10.1016/j.jaac.2020.08.088. Full Text

Childress, Ann Catherine, et al. “5.26 STARS-ADJUNCT: AKL-T01, A DIGITAL TREATMENT FOR PEDIATRIC ADHD AS AN ADJUNCT TO STIMULANT MEDICATION: RESPONSE RATES WITH REPEAT ADMINISTRATION.” Journal of the American Academy of Child & Adolescent Psychiatry, vol. 59, no. 10, Elsevier BV, 2020, pp. S157–S157. Crossref, doi:10.1016/j.jaac.2020.08.087. Full Text

Ann Catherine Childress, Scott H., et al. “5.10 EFFICACY AND SAFETY OF AN EXTENDED-RELEASE, ORALLY DISINTEGRATING METHYLPHENIDATE TABLET IN CHILDREN 6-12 YEARS OF AGE BASED ON ADHD RATING SCALE-IV SCORE AT BASELINE.” Journal of the American Academy of Child & Adolescent Psychiatry, vol. 59, no. 10, Elsevier BV, 2020, pp. S152–S152. Crossref, doi:10.1016/j.jaac.2020.08.070. Full Text

Epstein, Jeffery N., et al. “5.13 EXPLORING ENGAGEMENT AS A FACTOR FOR EFFICACY WITH AKL-T01, A HOME-BASED DIGITAL THERAPEUTIC.” Journal of the American Academy of Child & Adolescent Psychiatry, vol. 59, no. 10, Elsevier BV, 2020, pp. S153–S153. Crossref, doi:10.1016/j.jaac.2020.08.074. Full Text

Lunsford-Avery, J. R., et al. “SLEEP ASSOCIATED WITH EXECUTIVE FUNCTIONING AMONG ADOLESCENTS ACROSS THE ADHD CONTINUUM.” Sleep, vol. 43, 2020, pp. A373–A373.

Kollins, Scott H. “Duration of Effect of a Novel, Home-Based, Digital Treatment for Pediatric ADHD.” Journal of the American Academy of Child & Adolescent Psychiatry, vol. 58, no. 10, Elsevier BV, 2019, pp. S296–S296. Crossref, doi:10.1016/j.jaac.2019.09.008. Full Text

Kollins, Scott H. “37.4 COMPUTER-BASED AND PARENT-REPORTED ASSESSMENT OF EXECUTIVE FUNCTIONING: METHOD VARIANCE AND IMPLICATIONS FOR INTERPRETING FINDINGS FROM ADHD EFFICACY TRIALS.” Journal of the American Academy of Child & Adolescent Psychiatry, vol. 58, no. 10, Elsevier BV, 2019, pp. S356–S356. Crossref, doi:10.1016/j.jaac.2019.07.925. Full Text

Chen, S., et al. “A generic algorithm for sleep-wake cycle detection using unlabeled actigraphy data.” 2019 Ieee Embs International Conference on Biomedical and Health Informatics, Bhi 2019  Proceedings, 2019. Scopus, doi:10.1109/BHI.2019.8834568. Full Text

Childress, Ann Catherine, et al. “4.15 The Efficacy and Safety of Methylphenidate Hydrochloride (HCL) Extended-Release in Preschool Aged Children With ADHD.” Journal of the American Academy of Child & Adolescent Psychiatry, vol. 57, no. 10, Elsevier BV, 2018, pp. S209–S209. Crossref, doi:10.1016/j.jaac.2018.09.241. Full Text

Pages

Schrott, Rose, et al. Data from: Cannabinoid exposure and altered DNA methylation in rat and human sperm (null). 25 Aug. 2020. Manual, doi:10.7924/r4v122j79. Full Text